Autoimmune rheumatic diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren's Syndrome and progressive systemic sclerosis require both a genetic predisposition and an environmental exposure for disease onset and flares, and two or more of these diseases can develop in the same patient.
Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among antinuclear antibodies (ANA) positive healthy individuals (HI). We assessed the prevalence of anti-DFS70 antibodies in patients with and without ANA-associated rheumatic diseases (AARDs) by two methods: chemiluminescent immunoassay (CIA) and an indirect immunofluorescence (IIF) assay based on immunoadsorption for DFS70.
Not everything that glitters is gold. The case of polymyalgia rheumatica.
Cannabinoids for the treatment
of rheumatic diseases — where
do we stand?
Epidemiology of eight common rheumatic
diseases in China: a large-scale cross-sectional
survey in Beijing
Response to: 'Checkpoint inhibitor-induced
polymyalgia rheumatica controlled by
cobimetinib, a MEK 1/2 inhibitor' by Chan
The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases
Over the past decade, cannabis has re- emerged as a potential medicinal therapy, and its use in this context is increasingly becoming legalized throughout the world. Many of the current medical applications of cannabinoids include rheumatic diseases such as rheumatoid arthritis (RA) and fibromyalgia, prompting the need to evaluate the current evidence for therapeutic use in these conditions and prospective applications.
Rheumatic paraneoplastic syndromes – A clinical link between malignancy and autoimmunity